PERTH, Australia, 4th October 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to announce it has been granted a further US patent (US 2014/0141452 A1) covering the identification of Phylomers with the ability to enter specific endothelial cells in the brain.
Delivering cargoes into the brain endothelial cells is a first step towards developing better medicines for neurological conditions of the central nervous system. Discovering and developing medicines that target the brain is significantly impeded by the blood brain barrier, and more specifically, by brain endothelial cells which are resistant to foreign molecules. We have now shown that brain endothelial cells are accessible to Phylogica’s Phylomers and that these peptides could be candidates for delivering drug cargoes into the brain. The brain represents a large market with wide unmet need, which is expected to increase with an ageing population.
For further information please download PDF attached:
Download this document
